Treatment of Osteoporosis in Chronic Kidney Disease Population

Endocrinol Metab Clin North Am. 2024 Dec;53(4):525-529. doi: 10.1016/j.ecl.2024.08.006. Epub 2024 Sep 30.

Abstract

Osteoporosis is treated similarly in all patients with GFR greater than 30 mL/min. In patients with fragility fracture with a GFR less than 30 mL/min, correct diagnosis through biopsy and bone turnover markers of adynamic bone disease, hyperparathyroidism, osteomalacia, or osteoporosis is important because antiresorptive medications will not benefit a patient with adynamic bone disease.

Keywords: Chronic kidney disease mineral and bone disorders; Denosumab; End stage renal disease; Glomerular filtration rate; Osteomalacia; Osteoporosis.

Publication types

  • Review

MeSH terms

  • Bone Density Conservation Agents* / therapeutic use
  • Humans
  • Osteoporosis* / drug therapy
  • Osteoporosis* / etiology
  • Osteoporosis* / therapy
  • Renal Insufficiency, Chronic* / complications

Substances

  • Bone Density Conservation Agents